$ILMN News

How Investors May Respond To Illumina (ILMN) BioInsight AI Rollout

Here’s How Much You Would Have Made Owning Illumina Stock In The Last 20 Years

Illumina (ILMN) Reports Next Week: Wall Street Expects Earnings Growth

Illumina’s (ILMN) Strong Quarterly Beats on Revenue and Earnings Drive Share Gains

Illumina BioInsight Platform expands with new software to accelerate the path from sequencing to discovery

Illumina To Webcast Upcoming Investor Conference

Canaccord Genuity Maintains Hold on Illumina, Raises Price Target to $300

Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report?

$100 Invested In Illumina 15 Years Ago Would Be Worth This Much Today

Illumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs

Is Illumina (ILMN) Fully Valued Following Its Recall And AI Push?

Did Illumina’s (ILMN) New SpliceAI2 Genomic Model Just Reframe Its Clinical Genomics Narrative?

Illumina (ILMN) Starts Global Recall Of Diagnostic Sequencers Over Security Vulnerability

Illumina (ILMN) Stock May Be About Fair Value After Genomics AI Launch

Illumina Earnings Preview: What to Expect

TD Cowen Maintains Hold on Illumina, Raises Price Target to $270

Illumina’s (ILMN) Sequencing Business Is Recovering, But Is the Stock Getting Ahead of Itself?

What is Illumina’s (ILMN) Economic Moat, and is it Widening or Narrowing?

Illumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026

Illumina releases SpliceAI2 to help advance rare disease research